Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer

JJ Kim, T Kurita, SE Bulun - Endocrine reviews, 2013 - academic.oup.com
Progesterone receptor (PR) mediates the actions of the ovarian steroid progesterone, which
together with estradiol regulates gonadotropin secretion, prepares the endometrium for …

Endometrial cancer

F Amant, P Moerman, P Neven, D Timmerman… - The Lancet, 2005 - thelancet.com
Each year, endometrial cancer develops in about 142 000 women worldwide, and an
estimated 42 000 women die from this cancer. The typical age-incidence curve for …

Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review

CC Gunderson, AN Fader, KA Carson, RE Bristow - Gynecologic oncology, 2012 - Elsevier
OBJECTIVE: The objective of this review was to analyze published contemporary oncologic
and reproductive outcomes in women with endometrial hyperplasia or cancer undergoing …

Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and …

ID Gallos, J Yap, M Rajkhowa, DM Luesley… - American journal of …, 2012 - Elsevier
OBJECTIVE: The objective of the study was to evaluate the regression, relapse, and live
birth rates of early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH) …

[HTML][HTML] Theories of endometrial carcinogenesis: a multidisciplinary approach

ME Sherman - Modern Pathology, 2000 - Elsevier
Historical observations have suggested that endometrial carcinomas vary in histopathologic
appearance and clinical features. More recent, systematic studies have provided …

Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women

K Ushijima, H Yahata, H Yoshikawa… - Journal of clinical …, 2007 - ascopubs.org
Purpose To assess the efficacy of fertility-sparing treatment using medroxyprogesterone
acetate (MPA) for endometrial carcinoma (EC) and atypical endometrial hyperplasia (AH) in …

The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic …

SF Lax, B Kendall, H Tashiro, RJC Slebos… - Cancer, 2000 - Wiley Online Library
BACKGROUND The two most common types of uterine endometrial carcinoma,
endometrioid (UEC) and serous (USC), differ in their histopathologic appearance and …

Endometrial cancer: not your grandmother's cancer

JN McAlpine, SM Temkin, HJ Mackay - Cancer, 2016 - Wiley Online Library
Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the
highest disease burden is reported in North America and Western Europe. Although the …

[HTML][HTML] Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma …

M Koskas, J Uzan, D Luton, R Rouzier, E Daraï - Fertility and sterility, 2014 - Elsevier
Objective To evaluate the various possible prognostic factors on the fertility-sparing
management of atypical hyperplasia and endometrial cancer; to generate survival curves to …

[HTML][HTML] Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40

TC Randall, RJ Kurman - Obstetrics & Gynecology, 1997 - Elsevier
Objective: To determine the efficacy of conservative management of atypical hyperplasia
and well-differentiated carcinoma of the endometrium in women under age 40. Methods …